Insider Selling: BioLife Solutions, Inc. (NASDAQ:BLFS) COO Sells 1,500 Shares of Stock

BioLife Solutions, Inc. (NASDAQ:BLFSGet Rating) COO Greef Roderick De sold 1,500 shares of the company’s stock in a transaction dated Friday, November 18th. The shares were sold at an average price of $22.13, for a total value of $33,195.00. Following the completion of the sale, the chief operating officer now directly owns 93,719 shares of the company’s stock, valued at $2,074,001.47. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Greef Roderick De also recently made the following trade(s):

  • On Wednesday, November 16th, Greef Roderick De sold 1,500 shares of BioLife Solutions stock. The shares were sold at an average price of $23.21, for a total value of $34,815.00.
  • On Monday, November 14th, Greef Roderick De sold 20,000 shares of BioLife Solutions stock. The shares were sold at an average price of $23.86, for a total value of $477,200.00.
  • On Friday, October 7th, Greef Roderick De sold 8,552 shares of BioLife Solutions stock. The shares were sold at an average price of $22.69, for a total value of $194,044.88.
  • On Monday, October 3rd, Greef Roderick De sold 1,233 shares of BioLife Solutions stock. The shares were sold at an average price of $21.95, for a total value of $27,064.35.

BioLife Solutions Stock Down 0.2 %

BioLife Solutions stock opened at $21.20 on Monday. The stock’s 50 day moving average price is $22.32 and its 200 day moving average price is $19.12. BioLife Solutions, Inc. has a 1-year low of $10.40 and a 1-year high of $53.10. The company has a market cap of $906.64 million, a PE ratio of -8.55 and a beta of 1.78. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.68 and a quick ratio of 2.76.

Institutional Investors Weigh In On BioLife Solutions

Hedge funds and other institutional investors have recently bought and sold shares of the business. Truist Financial Corp acquired a new stake in shares of BioLife Solutions in the first quarter valued at about $208,000. SG Americas Securities LLC acquired a new stake in shares of BioLife Solutions during the 1st quarter valued at approximately $444,000. Peoples Bank OH boosted its stake in shares of BioLife Solutions by 3.3% during the 1st quarter. Peoples Bank OH now owns 48,775 shares of the medical equipment provider’s stock worth $1,109,000 after acquiring an additional 1,567 shares in the last quarter. abrdn plc grew its holdings in shares of BioLife Solutions by 1.4% in the 1st quarter. abrdn plc now owns 132,124 shares of the medical equipment provider’s stock worth $3,045,000 after acquiring an additional 1,824 shares during the period. Finally, Versor Investments LP acquired a new stake in shares of BioLife Solutions in the 1st quarter worth approximately $357,000. Institutional investors and hedge funds own 86.69% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have commented on BLFS shares. StockNews.com raised BioLife Solutions to a “sell” rating in a research note on Friday, November 11th. Stephens reduced their price objective on BioLife Solutions to $31.00 in a research note on Wednesday, November 16th. Finally, Cowen reduced their price objective on BioLife Solutions to $29.00 in a research note on Monday, August 15th.

About BioLife Solutions

(Get Rating)

BioLife Solutions, Inc develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.

Featured Stories

Insider Buying and Selling by Quarter for BioLife Solutions (NASDAQ:BLFS)

Receive News & Ratings for BioLife Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLife Solutions and related companies with MarketBeat.com's FREE daily email newsletter.